Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain

References

• Remington LT, Sligl WI. Community-acquired pneumonia. Curr Opin Pulm Med. 2014;20(3):215–224.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471.
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.
   PubMed Web of Science ®Google Scholar
• Rivero-Calle I, Pardo-Seco J, Aldaz P, et al. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). BMC Infect Dis. 2016;16(1):645.
   PubMedGoogle Scholar
• Yu H, Rubin J, Dunning S, et al. Clinical and economic burden of community-acquired pneumonia in the medicare fee-for-service population. J Am Geriatr Soc. 2012;60:n/a–n/a.
   Web of Science ®Google Scholar
• Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589–1592.
   PubMed Web of Science ®Google Scholar
• Torres A. Community-acquired pneumonia: changing paradigms about mortality. Community Acquir Infect. 2014;1:1.
   Google Scholar
• Reyes S, Martinez R, Vallés JM, et al. Determinants of hospital costs in community-acquired pneumonia. Eur Respir J. 2008;31(5):1061–1067.
   PubMed Web of Science ®Google Scholar
• Brown JD, Harnett J, Chambers R, et al. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. BMC Geriatr. 2018;18:92.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect. 2011;17:1.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Supplement_2):S27–S72.
   PubMed Web of Science ®Google Scholar
• Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–iii55.
   PubMed Web of Science ®Google Scholar
• Ott SR, Hauptmeier BM, Ernen C, et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur. Respir. J. 2012;39(3):611–618.
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Rodríguez-Hurtado D, Rodríguez-Hurtado D, et al. Characteristics and management of community-acquired pneumonia in the era of global aging. Med Sci. 2018;6:35.
   Google Scholar
• Menéndez R, Torres A, Aspa J, et al. [Community-acquired pneumonia. New guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)]. Arch Bronconeumol. 2010;46:543–558.
   PubMed Web of Science ®Google Scholar
• File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled‐blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community‐acquired pneumonia. Clin Infect Dis. 2010;51:1395–1405.
   PubMed Web of Science ®Google Scholar
• Eckburg PB, Friedland HD, Llorens L, et al. Day 4 clinical response of ceftaroline fosamil versus ceftriaxone for community-acquired bacterial pneumonia. Infect Dis Clin Pract. 2012;20(4):254–260.
   Google Scholar
• Ramani A, Udeani G, Evans J, et al. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. J Chemother. 2014;26(4):229–234.
   PubMed Web of Science ®Google Scholar
• Guervil DJ, Kaye KS, Hassoun A, et al. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP). J. Chemother. 2016;28(3):180–186.
   PubMed Web of Science ®Google Scholar
• Udeani G, Evans J, Cole P, et al. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients. Hosp Pract. 2014;42(3):109–115.
   Google Scholar
• de Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, et al. Trends in hospitalizations for community-acquired pneumonia in Spain: 2004 to 2013. Eur J Intern Med. 2017;40:64–71.
   PubMed Web of Science ®Google Scholar
• Ramirez J. A, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med. 1999;159(20):2449–2454.
   PubMedGoogle Scholar
• Ostermann H, Blasi F, Medina J, et al. Health economic analysis of current clinical management of patients hospitalised with community-acquired pneumonia across Europe (2010–2011) (REACH study). 22nd European Congress of Clinical Microbiology and Infectious Diseases, London, UK. 2012.
   Google Scholar
• Garau J. Current management of patients hospitalised with community acquired pneumonia across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. 22nd ECCMID, London, UK. Presentation; 2012.
   Google Scholar
• Rao N, Gibson E, Lawson R, et al. Zinforo (Ceftaroline Fosamil) versus other empiric antibiotics for moderateto-severe community acquired Pneumonia (CAP) in adults: A network meta-analysis. ISPOR 2016 – Poster, Vienna, Austria. 2016.
   Google Scholar
• Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med. 2006;100(12):2129–2136.
   PubMed Web of Science ®Google Scholar
• Welte T, Petermann W, Schurmann D, et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin Infect Dis. 2005;41(12):1697–1705.
   PubMed Web of Science ®Google Scholar
• File TM, Rewerska B, Vucinić-Mihailović V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016;63(8):1007–1016.
   PubMed Web of Science ®Google Scholar
• Leprince C, Desroches M, Emirian A, et al. Antimicrobial Susceptibility Studies Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study. Diagn Microbiol Infect Dis. 2015;83(2):175–182.
   PubMed Web of Science ®Google Scholar
• Botplusweb.portalfarma.com. BOT Plus 2. Base de Datos de Medicamentos [Internet]. [cited 2018 Sep 10]. Available from: https://botplusweb.portalfarma.com/botplus.aspx/.
   Google Scholar